伊沃赛单抗与化疗相较于替雷利珠单抗及化疗在中国Harmoni-6研究中降低鳞状非小细胞肺癌患者疾病进展或死亡风险40%

美股速递
Oct 19

伊沃赛单抗与化疗相较于替雷利珠单抗(PD-1抑制剂)加化疗,在中国进行的Harmoni-6研究中,在一线治疗鳞状非小细胞肺癌患者时,降低了疾病进展或死亡的风险40%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10